AXTQ’s green screen is the other side of AXT’s selloff
AXTQ targets twice the inverse daily move in AXTI. Its jump has a clear mechanical explanation, while a separate same-day AXT catalyst remains unverified.
Read the story
AXTQ targets twice the inverse daily move in AXTI. Its jump has a clear mechanical explanation, while a separate same-day AXT catalyst remains unverified.
Read the story
ETFsQBTZ seeks to rise when D-Wave falls. The inverse ETF’s gain follows results that paired revenue growth with a much faster increase in operating expenses.
ETFsMARA’s $500 million buyback plan helps explain the interest in MHX and MRAL. Daily leverage, thin trading and a longer decline complicate the rebound.

FutureFuel’s stronger sales and narrower loss are encouraging, but cash outflow clouds the recovery. Its next-quarter forecast now needs proof.

iHeartMedia sharply reduced its 2026 profit and cash-flow outlook. Radio advertising weakness and heavy debt help explain concerns behind the IHRT selloff.

Microvast’s sharp snapshot decline follows weaker sales, shrinking margins and an unresolved going-concern warning. Debt refinancing is now a central risk.

MIND CTI’s snapshot rally brings shares close to Enghouse’s proposed cash price. Approval, closing risk and the remaining merger spread now matter.

SMX’s new AI materials announcement adds to its sharp rally. The project remains in development, while a recent reverse split complicates historical comparisons.

PepGen’s sharp snapshot gain accompanies new DM1 trial data. Small patient numbers, an active U.S. clinical hold and future funding remain important.

SMX and Wellchange appear with strong gains in the supplied Penny Gems snapshot, but November 9 reverse splits make comparable prices and share counts essential context.

Netcapital has until February 9 to file overdue reports. The snapshot rally brings attention, while missing financial statements and separate SEC allegations remain key context.

The latest supplied CODX snapshot shows $0.45 and a 74.45% gain. India tuberculosis plans, November 10 earnings and convertible financing frame the business story.